RIGEL PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
RIGEL PHARMACEUTICALS, INC. (RIGL) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $22.50 million as of 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-05-05
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $22.50M.
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $7.50M.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $7.50M.
- 2025-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $7.50M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-03-31 | $22.50M 10-Q · filed 2026-05-05 |
| 2025-09-30 | $7.50M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $7.50M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $7.50M 10-Q · filed 2025-05-06 |
| 2024-03-31 | $7.50M 10-Q · filed 2024-05-07 |
| 2022-03-31 | $3.75M 10-Q · filed 2022-05-03 |
| 2021-03-31 | $1.67M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |